ZVRA
Zevra Therapeutics, Inc.
Biotechnology · Healthcare · United States
10.36
close · 2026-10-29
value
78
cheaper than peers78
quality
99
stronger fundamentals99
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 9.62× | 88 |
| price to sales | 5.01× | 73 |
| EV to EBITDA | 11.50× | 59 |
| price to book | 2.82× | 59 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 42.3% | 97 |
| debt to equity | 0.7% | 94 |
| return on equity | 34.8% | 91 |
| revenue growth | 53.3% | 67 |
4 of 4 measures available
Facts
| market cap | $615M |
| free cash flow | $48.4M |
| employees | 61 |
| first trade | 2015-04-16 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.35 | -2.28 | -1.30 | -1.20 |
| free cash flow | -$2.4M | -$69.7M | -$33.8M | -$18.8M |
| net income | $83.2M | -$105.5M | -$46.0M | -$26.8M |
| revenue | $106.5M | $23.6M | $27.5M | $10.2M |
| unusual items | $91.9M | $2.0M | $515,000 | -$3.1M |